Successful Treatment with Rituximab in a Patient with TTP Secondary to Severe ANCA-Associated Vasculitis

DOI Web Site 参考文献21件
  • Asamiya Yukari
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Moriyama Takahito
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Takano Mari
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Iwasaki Chihiro
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Kimura Kazuo
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Ando Yukako
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Aoki Akiko
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Kikuchi Kan
    Shimoochiai Clinic
  • Takei Takashi
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Uchida Keiko
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Nitta Kosaku
    Department of Medicine, Kidney Center, Tokyo Women's Medical University

この論文をさがす

抄録

We report a case of thrombotic thrombocytopenic purpura (TTP) secondary to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis treated by rituximab. TTP secondary to ANCA-associated vasculitis is very rare and has a high mortality rate. We employed rituximab and successfully treated TTP secondary to ANCA-associated vasculitis, because standard therapies, such as steroid therapy, intravenous pulse cyclophosphamide, and repeated plasma exchange (PE), did not suppress her disease activity. This is the first report to suggest that rituximab can achieve complete remission of TTP secondary to ANCA-associated vasculitis.<br>

収録刊行物

  • Internal Medicine

    Internal Medicine 49 (15), 1587-1591, 2010

    一般社団法人 日本内科学会

参考文献 (21)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ